2024 Honorary Advisors

Chairman & President

<span style="font-size: 15px;">Asia Financial Holdings Limited</span>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="https://img.hktdc.com/eyJidWNrZXQiOiJjbXMtaW1nbGliLXByZCIsImtleSI6ImFzaWFzdW1taXRnbG9iYWxoZWFsdGgvMjAyMjA2MTQva2g4MWI0eXUtWW1WeWJtRnlaQT09LnBuZyIsInJlZ2lvbiI6ImFwLXNvdXRoZWFzdC0xIiwiZm9ybWF0IjoicG5nIiwicXVhbGl0eSI6MTAwLCJlZGl0cyI6e319" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">The Hon Bernard Charnwut Chan, GBM, GBS, JP</span>Chairman &amp; President<br />Asia Financial Holdings Limited</div><p style="padding-top: 20px;">The Honourable Bernard Charnwut CHAN is the Chairman & President of Asia Financial Holdings Ltd., Chairman of Asia Insurance Co. Ltd., Chairperson of the Hong Kong Council of Social Service and Chairman of M Plus Museum. He previously served as a Hong Kong Deputy to the National People's Congress of the People's Republic of China, the Convenor of the Non-Official Members of the Executive Council of HKSAR, a Legislative Council Member, Chairman of Hong Kong Palace Museum, Chairman of the Council of Lingnan University, the Council for Sustainable Development and the Antiquities Advisory Board. He was awarded the Gold Bauhinia Star in 2006 and the Grand Bauhinia Medal in 2020..</p>

The Hon Bernard Charnwut Chan, GBM, GBS, JP

Chief Executive Officer

<span style="font-size: 15px;">Hong Kong Exchanges and Clearing Limited (HKEX)</span>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2024/04/Bonnie_Y_Chan.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Ms Bonnie Chan</span>Chief Executive Officer<br />Hong Kong Exchanges and Clearing Limited (HKEX)</div><p style="padding-top: 20px;">Bonnie Y Chan was appointed Chief Executive Officer of Hong Kong Exchanges and Clearing Limited on 1 March 2024.<br><br>Ms Chan brings more than 30 years of global capital markets leadership and expertise. She has played a leading role in supporting the transformation of Hong Kong’s listed market and infrastructure, enhancing market quality, attractiveness, and efficiency, and helping position HKEX as a leading global exchange group.<br><br>Ms Chan has held leadership roles in legal and financial services with Asia-Pacific and global responsibilities. Before becoming CEO, Ms Chan was HKEX’s Co-Chief Operating Officer, where she oversaw the Group’s key operational and strategic functions. Ms Chan first joined HKEX as Head of IPO Transactions in 2007 from Morgan Stanley, where she spent four years leading the legal function for the investment bank’s Asia capital markets business. She rejoined HKEX in 2020 as Head of Listing, after serving as a partner at international law firm Davis Polk & Wardwell focusing on capital markets between 2010 and 2019.<br><br>Ms Chan is a frequent contributor to the World Economic Forum and is a member of the Forum’s Centre for Financial and Monetary Systems Advisory Council.<br><br>In Hong Kong, Ms Chan served as a member of the Financial Services Development Council between 2015 and 2018, and was a member of its Board of Directors between 2019 and 2020. She was also a member of the Standing Committee of Company Law Reform and the Disciplinary Panel of the Hong Kong Institute of Certified Public Accountants.<br><br>Ms Chan was recognised as one of the World Federation of Exchanges’ Women Leaders between 2021 and 2023. She was also recognised among IFLR1000’s Asia Best Lawyers in 2019 and was named The American Lawyer’s Dealmaker of the Year in 2018.<br><br>Ms Chan holds a Bachelor of Laws from the University of Hong Kong and a Master of Laws from Harvard Law School. She is admitted as a solicitor in Hong Kong and an attorney at law in New York State. </p>

Ms Bonnie Chan

Founding Dean, Vanke School of Public Health, Tsinghua University;

<p>Emeritus Director General, World Health Organization</p>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/03/Margaret_Chan.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Dr Margaret Chan</span>Founding Dean, Vanke School of Public Health, Tsinghua University;<br />Emeritus Director General, World Health Organization</div><p style="padding-top: 20px;">Dr Margaret Chan, from the People’s Republic of China, obtained her medical degree from the University of Western Ontario in Canada. She joined the Hong Kong Department of Health in 1978, where her career in public health began.<br /><br />In 1994, Dr Chan was appointed Director of Health of Hong Kong，the first woman to hold that position. In her nine-year tenure as director, she launched new services to prevent the spread of disease and promote better health. She also introduced new initiatives to improve communicable disease surveillance and response, enhance training for public health professionals, and establish better local and international collaboration. She effectively managed outbreaks of avian influenza and of severe acute respiratory syndrome (SARS). <br /><br />In 2003, Dr Chan joined WHO as Director of the Department for Protection of the Human Environment. In June 2005, she was appointed Director, Communicable Diseases Surveillance and Response as well as Representative of the Director-General for Pandemic Influenza. In September 2005, she was named Assistant Director-General for Communicable Diseases. Dr Chan was elected to the post of Director-General on 9 November 2006. The Assembly appointed Dr Chan for a second five-year term at its sixty-fifth session in May 2012. Dr Chan’s last term began on 1 July 2012 and ended on 30 June 2017. <br /><br />On 2 April 2020, Dr Chan was appointed as inaugural Dean of Vanke School of Public Health, Tsinghua University, China.</p>

Dr Margaret Chan

Executive Director and Vice Chairlady

<div><p>Sino Biopharmaceutical Limited</p></div>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/05/Cheng_Cheung_Ling.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Ms Cheng Cheung Ling, JP</span>Executive Director and Vice Chairlady<br />Sino Biopharmaceutical Limited</div><p style="padding-top: 20px;">WORKING EXPERIENCE<br />Corporate duties:</p><ul><li>CEO of Chia Tai Pharmaceutical Group</li><li>Chairman of Beijing Tide Pharmaceutical Co., Limited</li><li>Vise-Chairlady of Sino Biopharmaceutical Limited</li></ul><p style="padding-top: 20px;"><br />SOCIAL DUTIES</p><ul><li>Chairman of Belt and Road General Chamber of Commerce</li><li>Member of the 12th CPPCC National Committee</li><li>President of HKCPPCC (Provincial) Members Association</li><li>Standing Committee of All-China Federation of Industry and Commerce</li><li>Eighth, Ninth, Tenth and Eleventh Shaanxi Provincial CPPCC Standing Committee, Shaanxi Provincial PPCC Hong Kong members Convenor</li><li>China Overseas Friendship Association Standing Committee</li><li>Vice President of Shaanxi Provincial Federation of Industry and Commerce</li><li>Honorary President of Shaanxi Federation of Qin Businessmen</li><li>Vice Chairman of Friends of Hong Kong Association Development Fund</li><li>President of Hong Kong Shaanxi Friendship Association</li><li>Member of Converted Efforts Resource Centre</li><li>Vice President of China Association of Women Entrepreneurs</li><li>Vice President of Beijing Private Sci-Tech Promotion Association</li></ul><p style="padding-top: 20px;"><br />HONORARY TITLES</p><ul><li>Top 10 Innovators in China's Economy in 2018</li><li>2018 New Economy Person of the Year</li><li>2018 Outstanding Business Women Leaders</li><li>Outstanding Contributors to China's Pharmaceutical Industry in 2018</li><li>2017 China Social Responsibility Outstanding Person Award</li><li>2017 Top Ten Business Leaders in China's Pharmaceutical Industry</li><li>Top 10 business leaders in China’s economy in 2016</li><li>Top 10 outstanding women in China’s economy in 2016</li><li>Contribution Award from the seventh “Beijing DaXing District and Beijing Economic-Technological Development Area” in 2016</li><li>The leader of the Global Qin business in 2016</li><li>The Mulan Award of China’s medicine industry in 2016</li></ul><p style="padding-top: 20px;"><br />INTERESTS<br />reading, interior design, playing chess</p>

Ms Cheng Cheung Ling, JP

Chairman & CEO

<span style="font-size: 15px;">First Eastern Investment Group
</span>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="https://www.asiasummitglobalhealth.com/conference/asgh/wp-content/uploads/sites/36/2024/03/Victor_Chu.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Mr Victor L L Chu </span>Chairman &amp; CEO<br />First Eastern Investment Group</div><p style="padding-top: 20px;">Victor Chu was born in Canton, China and came to Hong Kong at the age of four. He received his early education in Hong Kong and England, and took his law degree at University College London (UCL) where he is now Chairman of the University’sgoverning council.<br /><br />Mr Chu is Chairman and CEO of First Eastern Investment Group, a leading Hong Kong-based international investment firm and a pioneer of private equity investments in China. He is a Co-Founderand Director of Peach Aviation in Japan, as well as a Board Member of AirbusSEand Nomura Holdings.<br /><br />Over the last 30+years, Victor Chu has at various times served as Director and Council Member of the Hong Kong Stock Exchange, Member of the Hong Kong Takeovers and Mergers Panel, Advisory Committee Member of the Securities and Futures Commission, and part-time member of Hong Kong Government’s Central Policy Unit. MrChu has also served as a Foundation Board Member (Trustee) of the World Economic Forum from 2003 to 2015 and currently co-chairs the Forum’s International Business Council. He is Chairman of the Hong Kong-Europe Business Counciland Chairman ofthe Hong Kong-United States Business Council.<br /><br />Mr Chu is admitted to practise law in England and Hong Kong. Since 1982 he has practised in the field of corporate, commercial and securities laws, with special emphasis on regional investment transactions. He served as Deputy Secretary-General of the International Bar Association (IBA) from 1995 to 2000.<br /><br />Victor Chu is a Trustee of Asia House in London and Hong Kong, as well as a member of the advisory boards of Chatham House, the Oxford Martin School and the Atlantic Council of the USA.<br /><br />Mr Chu was awarded the 2011 Global Economy Prize by the Kiel Institute for the World Economy.</p>

Mr Victor L L Chu

Chairman, IP Group;

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/04/Douglas_Flint.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Sir Douglas Flint, CBE</span>Chairman, IP Group;<br />Chairman, abrdn IP Group</div><p style="padding-top: 20px;">Sir Douglas is Chairman of abrdn plc, one of Europe’s largest investment and wealth managers. He is also Chairman of IP Group plc, which invests to accelerate commercialisation of science and technology based early-stage companies involved in life sciences, cleantech and deep technology. He has for many years been involved with Cancer Research UK where he chairs their corporate partnership board and since December 2022 Sir Douglas has been Chairman of the Royal Marsden Hospital and Charity. The Royal Marsden is the UK’s leading cancer hospital dedicated to cancer diagnosis, treatment, research and education.<br /><br />Douglas retired as Group Chairman of HSBC Holdings plc on 30th September 2017, having been appointed to that role in December 2010. For fifteen years prior to this he was HSBC’s Group Finance Director, joining from KPMG where he was a partner. During his HSBC career, Mr Flint was a member of both the Mayor of Beijing’s and the Mayor of Shanghai’s International Business Leaders’ Advisory Councils and served on the International Advisory Board of the China Europe International Business School. He was also up until his retirement, Chair of City UK's China Market Advisory Group.<br /><br />Between 2005 and 2011 he was also a Non-Executive Director of BP plc.<br /><br />In June 2006 Mr Flint was honoured with a CBE, and received his Knighthood in 2018, both awards in recognition of his services to the finance industry.</p>

Sir Douglas Flint, CBE

Chief Region Leader

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2024/05/andy_ho.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Mr Andy Ho</span>Chief Region Leader<br />Philips Greater China</div><p style="padding-top: 20px;">Andy Ho joined Royal Philips in August 2015 and is now the President of Greater China, and a member of the Global Executive Committee, Royal Philips.</p><p>Prior to joining Philips, Andy worked for over 30 years at IBM where he had held a wide range of sales, technology and senior management roles in Greater China, Canada and the United States. He had managed the Systems and Technologies Business in the Growth Market Region of the company across over 100 countries and was also a member of the company’s Global Technology Team Committee and Global Strategy Team Committee.</p><p>Andy holds a Bachelor’s Degree in Business Administration awarded by the Chinese University of Hong Kong.</p>

Mr Andy Ho

President

<p>CK Life Sciences Int’l., (Holdings) Inc.</p>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/02/H_L.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Mr H. L. Kam</span>President<br />CK Life Sciences Int’l., (Holdings) Inc.</div><p style="padding-top: 20px;">Mr H. L. KAM is an executive director of a number of CK Group companies, namely President of CK Life Sciences Int’l., (Holdings) Inc., Group Managing Director of CK Infrastructure Holdings Limited, Deputy Managing Director of CK Hutchison Holdings Limited and Deputy Managing Director of CK Asset Holdings Limited. <br /><br />Mr Kam is also the Chairman of Hui Xian Asset Management Limited, which manages Hui Xian Real Estate Investment Trust, a real estate investment trust listed on The Stock Exchange of Hong Kong and is the Chairman of Beijing Oriental Plaza Co., Ltd.<br /><br />Mr Kam is an Honorable Citizen of various cities in China, namely Shenyang of Liaoning Province, as well as Jiangmen, Foshan and Nanhai of Guangdong Province. <br /><br />In addition to being an Honorary Advisor of the Asia Summit on Global Health of Hong Kong Trade Development Council, he is also an Honorary Advisor of the Belt &amp; Road Summit of Hong Kong Trade Development Council, a Council Member of The Hong Kong Management Association, a Council Member of Hong Kong Beijing Association, a Council Member of Hong Kong &amp; Macau AustCham, a Member of the New Zealand Business Advisory Board as well as a Governor to the Governor's Council of the Hong Kong Canadian Chamber of Commerce.</p>

Mr H. L. Kam

Group Chairman, Nan Fung Group;

<p>Group Chairman &amp; Co-Founder, New Frontier Group</p>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/02/Antony_Leung.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Mr Antony Leung</span>Group Chairman, Nan Fung Group<br />Group Chairman & Co-Founder, New Frontier Group</div><p style="padding-top: 20px;">Mr Antony Leung, former Financial Secretary of Hong Kong Special Administrative Region, is Group Chairman of Nan Fung Group, a leading regional conglomerate focusing on property, investment and life sciences businesses. He is also Group Chairman & Co-Founder of New Frontier Group, one of the leading privately owned health care businesses in China, and Chairman & Co-Founder of Solomon Learning Group, a Hong Kong-based social enterprise that promotes education of money and morals. Concurrently, Mr Leung is the chairman of two charity organizations - Heifer Hong Kong and Food Angel as well as an Independent Non-Executive Director of China Construction Bank.<br /><br />Mr Leung also had extensive experience in financial services, including Chairman of Greater China of Blackstone, Chairman of Asia of JP Morgan Chase, Asia Head of Citi Private Bank, Regional Head of Citi Investment Bank, Treasury and Greater China.  In addition, he was Independent Director of China Merchants Bank, Industrial and Commercial Bank of China, China Mobile (Hong Kong) Limited, American International Assurance (Hong Kong) Limited, International Advisory Board Member of China Development Bank and Chairman of Harvard Business School Association of Hong Kong. His past public service included Non-Official Member of the Executive Council, Chairman of Education Commission, Chairman of University Grants Committee, Member of Exchange Fund Advisory Committee, Director of Hong Kong Airport Authority and Hong Kong Futures Exchange, Member of the Preparatory Committee and Election Committee for the Hong Kong Special Administrative Region and Hong Kong Affairs Advisors.</p>

Mr Antony Leung, GBS, OBE, JP

Managing Partner

<span style="font-size: 15px;">Qiming Venture Partners</span>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="https://img.hktdc.com/eyJidWNrZXQiOiJjbXMtaW1nbGliLXByZCIsImtleSI6ImFzaWFzdW1taXRnbG9iYWxoZWFsdGgvMjAyMTA4MDMvYWptNDM2by1UbWx6WVMxUmFXMXBibWM9LmpwZWciLCJyZWdpb24iOiJhcC1zb3V0aGVhc3QtMSIsImZvcm1hdCI6ImpwZWciLCJxdWFsaXR5IjoxMDAsImVkaXRzIjp7fX0=" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Ms Nisa Leung, MH, JP</span>Managing Partner<br />Qiming Venture Partners</div><p style="padding-top: 20px;">Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 530 portfolio companies.<br /><br />She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others.<br /><br />Nisa has been recognized by the Forbes Midas List for five consecutive years in 2019, 2020, 2021, 2022 and 2023, and named Best Women VCs List by Forbes China (#1 in 2022, #2 in 2021) and Most Powerful Women in Business by Fortune China in 2022.<br /><br />Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited (“HKEX”), Board Member of Hong Kong Palace Museum, Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA.</p>

Ms Nisa Leung, MH, JP

Chairman

<span style="font-size: 15px;">Elderly Commission</span>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/01/Donald_Li.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Dr Donald Li, SBS, JP</span>Chairman<br />Elderly Commission</div><p style="padding-top: 20px;">Dr Donald Li is a specialist in Family Medicine and private practice in Hong Kong, Shenzhen and Shanghai. He is the Chairman of Elderly Commission. He is the Past President of the World Organisation of Family Doctors (WONCA) and Censor of the Hong Kong College of Family Physicians. He is the Past President of Hong Kong Academy of Medicine.<br /><br />Dr Li is Honorary Clinical Professor in Family Medicine and Primary Care of The University of Hong Kong, Honorary Clinical Professor in Family Medicine of The Chinese University of Hong Kong, Honorary Professor of Shanghai Medical College of Fudan University. He is a registered Mainland China medical practitioner and has contributed to the training and development of family medicine in mainland for over twenty years. He advises and serves as director on listed companies associated with medical health and welfare. He is senior advisor and a Director of Jiahui International Health and medical director of Jiarong Clinic in Shenzhen .<br /><br />Dr Li is an active member of many Hong Kong governmental, non-government organization and public health bodies. He is Chairman of the Elderly Commission of Hong Kong SAR government , the Chairman of Action Committee Against Narcotics of Narcotics Division of Security Bureau, Honorary Consultant of Department of Health, member of the Steering Committee on Primary Healthcare Development of Food & Health Bureau, Chairman of the Board of Directors of the Hong Kong Sheng Kung Hui Welfare Council, Director of the Hong Kong St. John Ambulance Association, Honorary Steward of Hong Kong Jockey Club, Chairman of Professional Committee on Medical Health of Belt and Road General Chamber of Commerce.</p>

Dr Donald Li, SBS, JP

<span style="font-size: 15px;">HK Bio-Med Innotech Association</span>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2024/03/Yuk_Lam_Lo.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Prof Lo Yuk Lam, BBS</span>President<br />HK Bio-Med Innotech Association</div><p style="padding-top: 20px;">Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. <br /><br />Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology. He is also the Honorary Founding Chairman of Hong Kong Biotechnology Organization. In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China.<br /><br />Professor Lo was heavily involved in several committees of the HKSAR Government. He had been served as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, Director of the Hong Kong Applied R&amp;D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry &amp; Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR.<br /><br />In Mainland China, Professor Lo was a member of Chinese People’s Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the “Pericles International Prize” in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades. <br /><br />In the business sector, Professor Lo had been served as the Chairman of Asia Pacific of PerkinEImer (NYSE: PKI) and the President of Asia Pacific of Bio-Rad Laboratories (NYSE: BIO). Currently he is the Chairman of GT Healthcare Capital Partners, and Partner &amp; Investment Committee Member of Hongsen Investment Management Limited. As at the date of this annual report, Professor Lo holds directorships in the following listed companies:</p><table width="100%"><tbody><tr><td width="40%"><strong>Name of the listed company</strong></td><td width="30%"><strong>Term</strong></td><td width="30%"><strong>Position</strong></td></tr><tr><td><strong>Luye Pharma Group Limited (02186.HK)</strong></td><td>June 2014 to present</td><td>Independent Non-executive Director</td></tr><tr><td><strong>Sinovac Biotech Ltd. (SVA: NASDAQ)</strong></td><td>March 2006 to present</td><td>Independent Director</td></tr><tr><td><strong>Zhaoke Ophthalmology Limited (06622.HK)</strong></td><td>April 2021 to present</td><td>Independent Non-executive Director</td></tr></tbody></table>

Prof Lo Yuk Lam, BBS

Steward, Sequoia Capital

<p>Founding & Managing Partner, Sequoia China</p>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/03/Neil_Shen.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Mr Neil Shen</span>Steward, Sequoia Capital<br />Founding &amp; Managing Partner, Sequoia China</div><p style="padding-top: 20px;">Neil Shen is the Founding &amp; Managing Partner of Sequoia China. He is also Co-Founder of Trip.com (NASDAQ: TCOM) and Homeinns Hotel Group (NASDAQ: HMIN).<br /><br />Neil Shen serves on a number of philanthropic and public organizations and industry associations, including as a Member of the International Advisory Council of Hong Kong Exchanges and Clearing Market, Chairman of Yale SOM Board of Advisors, Chairman of Yale Center Beijing Executive Council, Trustee of Asia Society, Trustee of Shanghai Jiao Tong University, Trustee of Westlake University, Founder and Chairman of Hong Kong X-Tech Startup Platform and Hong Kong X Foundation, and Board Member of M Plus Museum.<br /><br />Neil Shen has received numerous honors and awards in China and across the globe. He held the top position in the Midas List by Forbes from 2018 to 2020 and 2023. When he reached the top of The Midas List 2018, it marked a milestone - the first time a Chinese national has hit the top of the list. He has been the highest-ranking Chinese investor on The Midas List on the Midas List from 2012 to 2023, and also is listed in the "100 Greatest Living Business Minds" by Forbes. In addition, he was listed on the "50 Most Influential Business Leaders in China" and "30 Most Influential Investors in China" by Fortune for the years 2015 to 2022, and "Top 20 Venture Capitalists Worldwide" by New York Times and CB Insights from 2016 to 2019.<br /><br />He received his Master's degree from Yale University and Bachelor's degree from Shanghai Jiao Tong University.</p>

Mr Neil Shen

Chair

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/03/Jon_Symonds.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Sir Jonathan Symonds, CBE</span>Chair<br />GSK</div><p style="padding-top: 20px;">Jon was appointed to the Board of GSK as Chair on 1 September 2019.<br /><br />Jon has extensive international financial, life sciences and governance experience.<br /><br />2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc, Chief Financial Officer of Novartis AG, Partner and Managing Director of Goldman Sachs, Chief Financial Officer of AstraZeneca plc, and a Partner at KPMG. His governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc and Non-Executive Chair of Proteus Digital Health Inc.<br /><br />Jon is a Fellow of the Institute of Chartered Accountants in England and Wales.<br /><br />External appointments</p><ul><li>Non-Executive Director, Rubius Therapeutics, Inc</li><li>Non-Executive Director, Genomics England Limited having previously served as its Chair</li><li>Life Sciences Champion</li><li>Member, European Round Table for Industry</li><li>Senior Advisor to Chatham House</li></ul>

Sir Jonathan Symonds, CBE

Representative Director, Chair of the Board of Directors,

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2024/06/Tatsuo_Yasunaga.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Mr Tatsuo Yasunaga</span>Representative Director, Chair of the Board of Directors<br />Mitsui &amp; Co., Ltd</div><p style="padding-top: 20px;">Tatsuo Yasunaga is the Chair of the Board of Directors at Mitsui &amp; Co. He was previously President and Chief Executive Officer for the Group between 2015 and 2021.<br /><br />Under his leadership, Mitsui successfully repositioned itself for future success by transforming and expanding its core business while at the same optimizing its portfolio. The Group also focused on new areas of growth, including energy solutions, healthcare/nutrition, and market Asia, driven by the creation of multifaced values and opportunities from digitalization, decarbonization, and consumers.<br /><br />He has held various senior positions with the Group around the globe, including in Asia, North and Latin America, Europe, and the Middle East. Over the course of his illustrious career, he has gained diverse and deep business experience including stints at the World Bank and Toyo Engineering Corporation.<br /><br />He first joined Mitsui in 1983, and in 2010 he served as the General Manager of the Corporate Planning ＆ Strategy Division, where he led the formulation of its medium-term management strategy and business plans. He then became the Chief Operating Officer of the Integrated Transportation Systems Business Unit in 2013, driving growth for the segment through projects across various fields including automotive, construction machinery, shipping, aerospace and railway. During his tenure, he also initiated strategic initiatives in railway infrastructure and truck-leasing to expand the segment and enhance its competitiveness.<br /><br />His motto in business is to “know and respect your partners”. Throughout his time at Mitsui, he studied the language, history and culture of each nation where he spent time.<br /><br />By personally visiting the countries where Mitsui operates in, he also hopes to show the importance of active dialogue with customers and partners with the aim of realizing 360° business innovation.</p>

Mr Tatsuo Yasunaga

Co-founder and Chairman

<span style="font-size: 15px;">Tigermed</span>

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2024/02/Ye_Xiaoping.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Dr Ye Xiaoping</span>Co-founder and Chairman<br />Tigermed</div><p style="padding-top: 20px;">Xiaoping Ye, male, born in Jiaxing, Zhejiang Province, EMBA of Guanghua School of Management, Peking University, obtained PhD in Oxford University UK. Co-founder and Chairman of Hangzhou Tigermed Consulting Co., Ltd.<br /><br />In 2004, Ye founded Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ/3347.HK), and is currently the chairman of the company. In past years, he was awarded many honorary titles, such as ‘2009 Top 25 Outstanding Entrepreneurs in China’, ‘2016 Professional Excellence Award’, ‘2019 Outstanding Entrepreneur in High-quality Management Development’, Imperial College China Alumni Association - Distinguished Alumni Title.<br /><br />Tigermed that he founded is a trusted clinical research organization, it provides full-service for the global biopharmaceutical and medical device industries. In past five years, the company has provided services for 52.9 percent of Class I new medicine approvals in China. In 2021, the company's operating income was 5.214 billion RMB, an increase of 63.32%, and the net profit attributable to the holding company was 2.874 billion RMB, an increase of 64.26%. The income from overseas main business was 2.447 billion RMB, up 91.87% year on year. Overcoming the impact of the epidemic, Tigermed achieved operating income of 5.65 billion RMB, rose 4.52% compared with a year earlier in the first three months of 2023.<br /><br />In recent years, Tigermed has also won the 2019 Zhejiang Corporate Social Responsibility Award, Frost &amp; Sullivan's 2021 China Clinical Contract Research Organization (CRO) Competitive Strategic Leadership Award and many other honor titles.</p>

Dr Ye Xiaoping

Co-founder, Chief Executive Officer and Chairman

<div style="display: inline-block;"><img style="max-width: 200px; width: 90%; border-radius: 100px;" src="/conference/asgh/wp-content/uploads/sites/36/2024/02/Yu_Xuefeng.jpg" /></div><div style="display: inline-block;"><span class="text-level-body theme-text text-font-bold line-limit-2 StandLogo_title__1142i">Dr Yu Xuefeng</span>Co-founder, Chief Executive Officer and Chairman<br />CanSino Biologics</div><p style="padding-top: 20px;">Dr Yu Xuefeng is the current Chairman and Chief Executive Officer of CanSinoBIO, primarily responsible for overseeing strategic development, overall operations and management as well as being the major decision-making force of CanSinoBIO. He received a master's degree in microbiology from the Department of Biology of Nankai University and a doctor's degree in microbiology from McGill University in Canada. In 1998, he joined Sanofi-Pasteur, one of the world's five largest vaccine companies, and served as Director of the Canadian Division of Bacterial Vaccine Development and Global Director of Bacterial Vaccine Development.<br /><br />In 2009, Dr Yu led his team to return to China to establish CanSinoBIO, specializing in the research and development, production and marketing of high-quality human vaccines. Dr Yu has been deeply engaged in the field of biomedicine for more than 30 years, and has rich experience in the development and operation management of biological products industry. He led the team to establish a rich vaccine research and development pipeline covering more than 10 infectious diseases. The commercialized products include the global innovative Recombinant novel coronavirus vaccine, the inhaled novel coronavirus vaccine and first in China ACYW135 meningococcal polysaccharide conjugate vaccine.<br /><br />Dr Yu also led the construction of the CanSinoBIO's vaccine production site, which was designed, constructed and operated in accordance with China and international GMP standards. Under the leadership of Dr Yu, CanSinoBIO team successfully completed H-share listing on the main board of the Hong Kong Stock Exchange and A-share listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, and continues to introduce a number of high-quality and innovative vaccines to the domestic and international markets, contributing to the cause of global public health.</p>

Dr Yu Xuefeng

<div class="container organizer" style="padding: 30pt 0pt 20pt 0pt;">
  <h3 style="color: #5cb8b2;padding-bottom: 20pt">Organisers</h3>
  <div><a href="http://www.gov.hk/en/residents/" target="_blank" rel="noopener noreferrer"><img style="padding: 0px 30px 50px 5px;" src="/conference/asgh/wp-content/uploads/sites/36/2023/04/HKSAR.jpg" alt="hksar" border="0" /></a> <a href="http://www.hktdc.com" target="_blank" rel="noopener noreferrer"> <img style="padding: 0px 0px 50px 0px;" src="https://www.asianfinancialforum.com/conference/aff/wp-content/uploads/sites/43/2022/12/logo_hktdc.jpg" alt="HKTDC" border="0" /> </a></div>
</div>


About the Summit

Honorary Advisors (2026)

Steering Committee (2026)

ASGH Brochure

Join ASGH Community

Previous Summit